SCHEMBL805512

SCHEMBL805512

CCCc1ccnc(C)n1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.42
LMNA P02545 2/20 0.42
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
NOS2 P35228 2/20 0.41
SREBF2 Q12772 8/20 0.39
NOS3 P29474 1/20 0.38
NOS1 P29475 1/20 0.38
MAPT P10636 2/20 0.38
ATM Q13315 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
ALDH1A1 P00352 1/20 0.38
KCNH2 Q12809 1/20 0.36
PDK2 Q15119 3/20 0.36
GRM4 Q14833 1/20 0.35
TLR8 Q9NR97 1/20 0.35
PDK4 Q16654 2/20 0.34
RECQL P46063 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18072486 0.88 KCNH2 (0.47) KDM4ELMNACYP3A4TSHRNOS2
SCHEMBL11561943 0.86 KCNH2 (0.55) KDM4ENOS2L3MBTL1ALDH1A1KCNH2
SCHEMBL17053275 0.84 KCNH2 (0.58) KDM4ELMNACYP3A4NOS2L3MBTL1
SCHEMBL22298878 0.84 KCNH2 (0.58) KDM4ELMNACYP3A4NOS2L3MBTL1
SCHEMBL30481675 0.82
SCHEMBL805491 0.82
SCHEMBL12831941 0.79 GRM4 (0.31) GRM4
SCHEMBL27592765 0.78 KDM4E (0.42) KDM4ELMNACYP3A4TSHRNOS2
SCHEMBL2262446 0.78 KDM4E (0.33) KDM4ELMNANOS2MAPTALDH1A1
SCHEMBL10468472 0.77 KDM4E (0.44) KDM4ELMNACYP3A4TSHRNOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4925901-A STORAGE STAABILITY, ONIUM ION CATALYST THE DOW CHEMICAL COMPANY (US) 1990-05-15 US claimed
WO-2023150394-A1 METHODS FOR TREATMENT OF CANCER FRONTIER MEDICINES CORPORATION (US) 2023-08-10 WO disclosed
EP-3265447-B1 BENZOXAZINE LOW TEMPERATURE CURABLE COMPOSITION HUNTSMAN ADVANCED MAT AMERICAS LLC (US) 2023-03-01 EP disclosed
CN-107428708-B Benzoxazine low temperature curable compositions 亨斯迈先进材料美国有限责任公司 2021-11-09 CN disclosed
WO-2018128720-A1 URACIL CONTAINING COMPOUNDS CV6 THERAPEUTICS (NI) LIMITED (GB) 2018-07-12 WO disclosed
WO-2018098207-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2018-05-31 WO disclosed
US-20180030264-A1 Benzoxazine Low Temperature Curable Composition HUNTSMAN ADVANCED MATERIALS AMERICAS LLC 2018-02-01 US disclosed
EP-3265447-A1 BENZOXAZINE LOW TEMPERATURE CURABLE COMPOSITION Huntsman Advanced Materials Americas LLC (US) 2018-01-10 EP disclosed
US-20160194303-A1 HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME NOGRA PHARMA LIMITED (IE) 2016-07-07 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed
US-20080146569-A1 Nicotinamide Derivatives PFIZER INC. 2008-06-19 US disclosed
EP-0458502-B1 Latent catalysts, cure-inhibited epoxy resin compositions and laminates prepared therefrom DOW GLOBAL TECHNOLOGIES INC (US) 2003-06-18 EP disclosed
EP-0328020-B1 Use of a catalyst in epoxy compositions DOW CHEMICAL CO (US) 1996-10-09 EP disclosed
US-5503937-A MIXTURE OF A COMPOUND HAVING MORE THAN ONE EPOXY GROUP, A DIHYDRIC PHENOLIC COMPOUND AND A LATENT CATALYST COMPRISING A SALT OF AN N-HETEROCYCLIC COMPOUND AND AN ACID HAVING A STRONG NUCLEOPHILIC ANION; COATINGS/MOLDINGS; STORAGE THE DOW CHEMICAL COMPANY (US) 1996-04-02 US disclosed
EP-0553887-A2 Catalysts and epoxy resin composition containing the same THE DOW CHEMICAL COMPANY (US) 1993-08-04 EP disclosed
US-5169473-A Complex of an onium, arsenic or amine compound and boric acid; advanced polyepoxides; storage stability THE DOW CHEMICAL COMPANY (US) 1992-12-08 US disclosed
US-5134239-A Quaterinary indolizine compound THE DOW CHEMICAL COMPANY (US) 1992-07-28 US disclosed
EP-0458502-A2 Latent catalysts, cure-inhibited epoxy resin compositions and laminates prepared therefrom THE DOW CHEMICAL COMPANY (US) 1991-11-27 EP disclosed
US-4925901-A STORAGE STAABILITY, ONIUM ION CATALYST THE DOW CHEMICAL COMPANY (US) 1990-05-15 US disclosed
EP-0328020-A2 Use of a catalyst in epoxy compositions THE DOW CHEMICAL COMPANY (US) 1989-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160194303-A1 HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME ICOS, NFATC1, CD74 KDM4E 1996/4885LMNA 4845/4885CYP3A4 1012/4885
US-20180030264-A1 Benzoxazine Low Temperature Curable Composition CRYZ, PIEZO1, PSMD12 KDM4E 471/4885LMNA 1771/4885CYP3A4 1284/4885
US-20080146569-A1 Nicotinamide Derivatives NNT, NAMPT, NADK KDM4E 3026/4885LMNA 1093/4885CYP3A4 315/4885
US-20120071461-A1 Substituted Benzamide Compounds BDKRB1, BDKRB2, HRH2 KDM4E 2727/4885LMNA 1463/4885CYP3A4 2055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.